2508 (2508) Fair Value & Analysis

Healthcare · Market cap HK$2.1B

2 2508 2508 · HK

PriceHK$3.33

Fair ValueHK$4.85

Upside+45.6%

Quality43/100

Watch 2508 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$3.65 – HK$6.06

Fair value as of: Jul 2, 2026

From 15 valuation models · updated today

Share price −13.3% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$3.32 – HK$8.80 · fair‑value band HK$3.65 – HK$6.06 · the HK$3.33 price screens below the HK$4.85 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2508 (2508) currently trades at HK$3.33, while our model-based Fair Value estimate is HK$4.85 — implying the stock looks roughly 45.6% undervalued today. We read business quality at 43/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 2508 generated revenue of HK$1.0B at a net margin of 39.0%. Revenue grew 35.3% year over year. The stock trades on a trailing P/E of 10.7. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.0B

Revenue growth (YoY) +35.3%

Net margin 39.0%

Free cash flow −HK$2.3M FY2025

P/E ratio 10.7

Operating margin 10.3%

More key figures

EPS (TTM) HK$0.0100

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2508 reported revenue of HK$1.0B in FY2025 versus HK$259M in FY2021, a compound +41.8%/yr. Reported net income was HK$408M in FY2025.

Revenue +41.8%/yr

FY21 HK$259M

FY22 HK$472M

FY23 HK$560M

FY24 HK$799M

FY25 HK$1.0B

Net income

FY21 −HK$119M

FY22 −HK$407M

FY23 −HK$239M

FY24 −HK$547M

FY25 HK$408M

Is 2508 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc H1CA34	R$97.60	R$115.75	+19%
Fresenius SE FSNUY	$11.27	$8.25	-27%
5225 5225	8.70 MYR	2.61 MYR	-70%
IHHHF IHHHF	$1.71	$1.26	-26%
Tenet Healthcare Corporation THC	$178.75	$300.86	+68%
Rede D'Or São Luiz S.A RDOR3	R$33.83	R$46.94	+39%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2508 (2508) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$4.85 versus a price of HK$3.33 — about +46% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 2508?

Our model-based fair value for 2508 is HK$4.85 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$3.33.

What is the quality score of 2508?

2508 has a Quality Score of 43/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2508 (2508)?

2508 reported trailing-twelve-month revenue of about HK$1.0B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2508?

The net profit margin of 2508 is about 39.0%, meaning it keeps roughly 39.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.